AR and prostate cancer: We reported previously that Casodex (bicalutamide), a specific inhibitor of AR, blocks the ability of G1 phase AR-positive LNCaP prostate cancer cells to enter S phase [14], [15], indicating a role of AR in cell cycle progression from G1 to S phase.